Hospital Ruber Internacional
Madrid, 28034, Spain
Location contact
Alvaro Beltran Corbellini, MD
CONTACT
Antonio Gil-Nagel, MD
PRINCIPAL_INVESTIGATOR
Antonio Gil-Nagel, MD, PhD
CONTACT
NCT Number: NCT06356233
This is a prospective observational study to evaluate the phenotype of 10 patients under 10 years of age with developmental epileptic encephalopathy due to mutation of the STXBP1 gene. The study will consist of a clinical and neurodevelopmental evaluation, magnetic resonance imaging, prolonged electroencephalogram, cardiological study, and analysis of biomarkers in cerebrospinal fluid. These patients will be followed up for 3 years. The aim of the study is, knowing the baseline phenotype, to analyse the response to commonly used drugs and to anticipate the response to different drugs available on the market in this group of patients based on clinical and biomarker assessment (EEG, MRI and study of specific proteins and neurotransmitters in plasma, urine and CSF).
Trial opening soon.
Get Notified1 month–10 year
All sexes
Observational
Madrid, 28034, Spain
Alvaro Beltran Corbellini, MD
CONTACT
Antonio Gil-Nagel, MD
PRINCIPAL_INVESTIGATOR
Antonio Gil-Nagel, MD, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention will be performed
Time frame: Baseline, 1 year and 2 years
Time frame: Baseline, 1 year and 2 years
Time frame: Baseline, 1 year and 2 years
Time frame: Baseline, 1 year and 2 years
Fundación Iniciativa para las Neurociencias (FINCE)
Other
Acronym: FIMBEX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01238250
15Q13.3 Deletion Syndrome, 15Q24 Deletion
Boston, Massachusetts, United States
View Trial DetailsNCT05161494
Central Nervous System Diseases, Congenital Abnormalities
Antwerp, Belgium
View Trial DetailsNCT06625112
Brain Diseases, Central Nervous System Diseases
Antwerp, Belgium
View Trial DetailsNCT06555965
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Epileptic Encephalopathy, Early Infantile, 4
Palo Alto, California, United States
View Trial Details